Clinical trials
Completed Polyneuropathies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 5 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| AstraZeneca | 2 |
| Odense University Hospital | 2 |
| The Catholic University of Korea | 2 |
| University of Rostock | 2 |
| Alnylam Pharmaceuticals | 1 |
| Austin Neuromuscular Center | 1 |
| Baxalta now part of Shire | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Polyneuropathies | 55 |
| Peripheral Nervous System Diseases | 9 |
| Amyloidosis | 8 |
| Amyloid Neuropathies, Familial | 7 |
| Critical Illness | 5 |
| Diabetes Mellitus | 5 |
| Diabetic Neuropathies | 5 |
| Neuralgia | 5 |
| Autoimmune Diseases | 4 |
| Muscle Weakness | 4 |
Trials
Showing 51 to 55 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.